A triple combination therapy of liraglutide, metformin, and TZD for 26 weeks in 533 subjects (1:1:1) randomized to once-daily liraglutide (1.2 or 1.8 mg) or liraglutide placebo in combination with metformin (1 g twice daily) and rosiglitazone (4 mg twice daily) demonstrated significantly greater mean HbA1c values in the liraglutide groups versus placebo (mean SE, -1.5 0.1% for both 1.2 and 1.8 mg liraglutide and -0.5 0.1% for placebo)
Key Features Research Use Only (RUO) compound 10 mg per bottle Spray format for convenient handling in laboratory settings Manufactured and packaged for research applications Product Specifications Compound Name: Melanotan II (MT2) Form: Spray Total Quantity: 10 mg per bottle Grade: Research Use Only (RUO) Intended Use This product is intended solely for laboratory research and investigational purposes
The ADCS-CGIC model included treatment, timepoint, treatment-by-timepoint interaction as the fixed effects, and participant as a random effect
Research Context This blend is supplied for laboratories conducting comparative cellular research involving the two component peptides
Mind the Shelf-Life: When reconstituted with bacteriostatic water, the solution remains stable and sterile for approximately 28 days
Frequent glucose monitoring and dose adjustment may be necessary for Insulin Glargine, U-300 in patients with kidney impairment [see Warnings and Precautions (5.3)]
